222 research outputs found
Recommended from our members
Factors affecting dairy farmers' attitudes towards antimicrobial medicine usage in cattle in England and Wales
There has been growing concern about bacterial resistance to antimicrobials in the farmed livestock sector. Attention has turned to sub-optimal use of antimicrobials as a driver of resistance. Recent reviews have identified a lack of data on the pattern of antimicrobial use as an impediment to the design of measures to tackle this growing problem. This paper reports on a study that explored use of antibiotics by dairy farmers and factors influencing their decision-making around this usage.
We found that respondents had either recently reduced their use of antibiotics, or planned to do so. Advice from their veterinarian was instrumental in this. Over 70% thought reducing antibiotic usage would be a good thing to do. The most influential source of information used was their own veterinarian. Some 50% were unaware of the available guidelines on use in cattle production. However, 97% thought it important to keep treatment records.
The Theory of Planned Behaviour was used to identify dairy farmersâ drivers and barriers to reduce use of antibiotics. Intention to reduce usage was weakly correlated with current and past practice of antibiotic use, whilst the strongest driver was respondentsâ belief that their social and advisory network would approve of them doing this. The higher the proportion of income from milk production and the greater the chance of remaining in milk production, the significantly higher the likelihood of farmers exhibiting positive intention to reduce antibiotic usage. Such farmers may be more commercially minded than others and thus more cost-conscious or, perhaps, more aware of possible future restrictions.
Strong correlation was found between farmersâ perception of their social referentsâ beliefs and farmersâ intent to reduce antibiotic use. Policy makers should target these social referents, especially veterinarians, with information on the benefits from, and the means to, achieving reductions in antibiotic usage. Information on sub-optimal use of antibiotics as a driver of resistance in dairy herds and in humans along with advice on best farm practice to minimise risk of disease and ensure animal welfare, complemented with data on potential cost savings from reduced antibiotic use would help improve poor practice
Case-control study to detect protective factors on pig farms with low Salmonella prevalence
The prevalence of Salmonella in UK pigs is amongst the highest in Europe, highlighting the risk to public health and the need to investigate on-farm controls. The objective of this study was to identify factors currently in operation on pig farms that had maintained a low Salmonella seroprevalence. For this purpose a case-control study was designed and pig farms with a low (\u3c10%) seroprevalence were compared against two randomly selected control farms, sharing the same geographical region and production type. A total of 11,452 samples, including pooled and individual floor faeces and environmental samples from pigs and their vicinity were tested and prevalence examined. In addition, detailed questionnaires were completed during the farm visits to collect descriptive data for risk factor analysis. It was shown that control farms had significantly higher prevalence compared to the case farms (19.4% and 4.3% for pooled and 6.7% and 0.1% for individual samples, respectively). The two risk factor analyses identified multiple variables associated with Salmonella prevalence including variables related to feed, effectiveness of cleaning and disinfection, biosecurity and batch production
Prevalence of Salmonella in the offspring of sows vaccinated with a live-attenuated Salmonella Typhimurium vaccine
In this study, the efficacy of a live-attenuated Salmonella Typhimurium vaccine administered to pregnant sows in the breeding herd was evaluated as a means of reducing the prevalence of Salmonella infection in growing and finishing pigs. The results suggest no significant difference between the prevalence of Salmonella (all serovars) in the two groups of sows and their offspring. The lymph node and meat juice collected from carcasses of offspring showed no significant difference between the two groups, but the prevalence of Salmonella was significantly lower in the caecum content from pigs born of vaccinated sows. The farm had a very low prevalence of S. Typhimurium, which may explain the failure to detect any effect of the vaccine, as the majority of Salmonella on this farm was S. Derby
Completeness of Communicable Disease Reporting, North Carolina, USA, 1995â1997 and 2000â2006
Reporting proportions were <50% for 49 of the 53 diseases evaluated
Resveratrol Targeting of Carcinogen-Induced Brain Endothelial Cell Inflammation Biomarkers MMP-9 and COX-2 is Sirt1-Independent
The occurrence of a functional relationship between the release of metalloproteinases (MMPs) and the expression of cyclooxygenase (COX)-2, two inducible pro-inflammatory biomarkers with important pro-angiogenic effects, has recently been inferred. While brain endothelial cells play an essential role as structural and functional components of the blood-brain barrier (BBB), increased BBB breakdown is thought to be linked to neuroinflammation. Chemopreventive mechanisms targeting both MMPs and COX-2 however remain poorly investigated. In this study, we evaluated the pharmacological targeting of Sirt1 by the diet-derived and antiinflammatory polyphenol resveratrol. Total RNA, cell lysates, and conditioned culture media from human brain microvascular endothelial cells (HBMEC) were analyzed using qRT-PCR, immunoblotting, and zymography respectively. Tissue scan microarray analysis of grade IâIV brain tumours cDNA revealed increased gene expression of Sirt-1 from grade IâIII but surprisingly not in grade IV brain tumours. HBMEC were treated with a combination of resveratrol and phorbol 12-myristate 13-acetate (PMA), a carcinogen known to increase MMP-9 and COX-2 through NF-ÎșB. We found that resveratrol efficiently reversed the PMA-induced MMP-9 secretion and COX-2 expression. Gene silencing of Sirt1, a critical modulator of angiogenesis and putative target of resveratrol, did not lead to significant reversal of MMP-9 and COX-2 inhibition. Decreased resveratrol inhibitory potential of carcinogen-induced IÎșB phosphorylation in siSirt1-transfected HBMEC was however observed. Our results suggest that resveratrol may prevent BBB disruption during neuroinflammation by inhibiting MMP-9 and COX-2 and act as a pharmacological NF-ÎșB signal transduction inhibitor independent of Sirt1
Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
Background & Aims
Interactions between C-C chemokine receptor types 2 (CCR2) and 5 (CCR5) and their ligands, including CCL2 and CCL5, mediate fibrogenesis by promoting monocyte/macrophage recruitment and tissue infiltration, as well as hepatic stellate cell activation. Cenicriviroc (CVC) is an oral, dual CCR2/CCR5 antagonist with nanomolar potency against both receptors. CVCâs anti-inflammatory and antifibrotic effects were evaluated in a range of preclinical models of inflammation and fibrosis.
Methods
Monocyte/macrophage recruitment was assessed in vivo in a mouse model of thioglycollate-induced peritonitis. CCL2-induced chemotaxis was evaluated ex vivo on mouse monocytes. CVCâs antifibrotic effects were evaluated in a thioacetamide-induced rat model of liver fibrosis and mouse models of diet-induced non-alcoholic steatohepatitis (NASH) and renal fibrosis. Study assessments included body and liver/kidney weight, liver function test, liver/kidney morphology and collagen deposition, fibrogenic gene and protein expression, and pharmacokinetic analyses.
Results
CVC significantly reduced monocyte/macrophage recruitment in vivo at doses â„20 mg/kg/day (p < 0.05). At these doses, CVC showed antifibrotic effects, with significant reductions in collagen deposition (p < 0.05), and collagen type 1 protein and mRNA expression across the three animal models of fibrosis. In the NASH model, CVC significantly reduced the non-alcoholic fatty liver disease activity score (p < 0.05 vs. controls). CVC treatment had no notable effect on body or liver/kidney weight.
Conclusions
CVC displayed potent anti-inflammatory and antifibrotic activity in a range of animal fibrosis models, supporting human testing for fibrotic diseases. Further experimental studies are needed to clarify the underlying mechanisms of CVCâs antifibrotic effects. A Phase 2b study in adults with NASH and liver fibrosis is fully enrolled (CENTAUR Study 652-2-203; NCT02217475)
Potential of Resveratrol Analogues as Antagonists of Osteoclasts and Promoters of Osteoblasts
The plant phytoalexin resveratrol was previously demonstrated to inhibit the differentiation and bone resorbing activity of osteoclasts, to promote the formation of osteoblasts from mesenchymal precursors in cultures, and inhibit myeloma cell proliferation, when used at high concentrations. In the current study, we screened five structurally modified resveratrol analogues for their ability to modify the differentiation of osteoclasts and osteoblasts and proliferation of myeloma cells. Compared to resveratrol, analogues showed an up to 5,000-fold increased potency to inhibit osteoclast differentiation. To a lesser extent, resveratrol analogues also promoted osteoblast maturation. However, they did not antagonize the proliferation of myeloma cells. The potency of the best-performing candidate in vitro was tested in vivo in an ovariectomy-induced model of osteoporosis, but an effect on bone loss could not be detected. Based on their powerful antiresorptive activity in vitro, resveratrol analogues might be attractive modulators of bone remodeling. However, further studies are required to establish their efficacy in vivo
Exploring institutional reform of Korean civil service pension: advocacy coalition framework, policy knowledge and social innovation
Abstract
This paper examines what factors are associated with the 2015 pension reform of Korean civil servant as social innovation. We explore what lessons we can learn from the pension reform in terms of the Advocacy Coalition Framework (ACF) model. The ACF model allows us to identify how the substantial reform is, relying on policy knowledge and entrepreneurs, possible in terms of political and social consensus. It also clearly demonstrates the possibility of systematic pension reform at an appropriate level through social learning and policy learning. Through the ACF model, we review how South Koreas civil servant pension reform act occurred at the end of May 2015. The temporal scope covers from 2009 latest reform, and the 2014s President administrative policy speech that had strongly been showed her will to reform the pension issue to the end of May 2015 when the reform bill enacted. We investigate each advocacy coalition in order to elucidate the actors that constitute the two coalition groups and to scrutinize whether a policy broker had existed in the process. We also attempt to find the relatively stable parameters and external events that affected the reform and also the belief system that shared by two advocacy coalition group. The result clearly shows that the two coalition groups shared their normative beliefs ultimately, for example, the need to change the current civil servants pension system, but, the gap in the numerical change in the policy core belief and secondary belief between the two actors had seemed to be excessively large and uncompromising. A policy broker who can coordinate the interests and interests of stakeholder groups over the government pension reform proposal was desperately needed. Negotiation and leadership of the policy entrepreneurs led to a settlement of the government pension reform proposal at the end of May 2015. Their entrepreneurial activities led to an appropriate level of social consensus on the sustainable reform of pension system through policy knowledge and learning. Further research is required to explore how models of socially innovative forms of governance are created in various pension reforms across various countries. It is also required to examine how policy entrepreneurs use policy knowledge and information for a successful institutional reform through social innovation across various countries
Physician privacy concerns when disclosing patient data for public health purposes during a pandemic influenza outbreak
Background: Privacy concerns by providers have been a barrier to disclosing patient information for public health\ud
purposes. This is the case even for mandated notifiable disease reporting. In the context of a pandemic it has been\ud
argued that the public good should supersede an individualâs right to privacy. The precise nature of these provider\ud
privacy concerns, and whether they are diluted in the context of a pandemic are not known. Our objective was to\ud
understand the privacy barriers which could potentially influence family physiciansâ reporting of patient-level\ud
surveillance data to public health agencies during the Fall 2009 pandemic H1N1 influenza outbreak.\ud
Methods: Thirty seven family doctors participated in a series of five focus groups between October 29-31 2009.\ud
They also completed a survey about the data they were willing to disclose to public health units. Descriptive\ud
statistics were used to summarize the amount of patient detail the participants were willing to disclose, factors that\ud
would facilitate data disclosure, and the consensus on those factors. The analysis of the qualitative data was based\ud
on grounded theory.\ud
Results: The family doctors were reluctant to disclose patient data to public health units. This was due to concerns\ud
about the extent to which public health agencies are dependable to protect health information (trusting beliefs),\ud
and the possibility of loss due to disclosing health information (risk beliefs). We identified six specific actions that\ud
public health units can take which would affect these beliefs, and potentially increase the willingness to disclose\ud
patient information for public health purposes.\ud
Conclusions: The uncertainty surrounding a pandemic of a new strain of influenza has not changed the privacy\ud
concerns of physicians about disclosing patient data. It is important to address these concerns to ensure reliable\ud
reporting during future outbreaks.University of Ottawa Open Access Author Fun
- âŠ